The consolidation of nanomedicine

Raphael Zingg*, Marius Fischer

*この研究の対応する著者

研究成果: Article査読

11 被引用数 (Scopus)

抄録

Over the past two decades, nanomedicine has grown steadily, however, without inducing a palpable shift in the diagnosis and treatment of diseases so far. While this may simply be a consequence of the slow, incremental nature that characterizes many modern technologies, this article posits that there is another set of significant factors harboring explanatory power. Uncertainties concerning safety, regulatory, and ethical requirements may have prompted innovators to stay close to the known and approved, eventually at the cost of innovating in unexplored alleys. Network analysis of all nanomedicine patents in the United States reveals that nanomedicine has indeed rather consolidated than expanded. We detail a set of recommendations that would reduce the uncertainty prevailing in nanomedicine and could contribute to pushing new boundaries. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.

本文言語English
論文番号e1569
ジャーナルWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
11
6
DOI
出版ステータスPublished - 2019 11 1

ASJC Scopus subject areas

  • バイオエンジニアリング
  • 医学(その他)
  • 生体医工学

フィンガープリント

「The consolidation of nanomedicine」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル